知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

11 records (took 0.018 seconds)

    BIOLOGICAL STATUS CLASSIFICATION
    1.
    发明申请
    BIOLOGICAL STATUS CLASSIFICATION 有权

    公开(公告)号：US20210033618A1

    公开(公告)日：2021-02-04

    申请号：US16943348

    申请日：2020-07-30

    Applicant: Randox Laboratories Ltd

    Inventor： Paul John Innocenzi ,  Stephen Peter Fitzgerald ,  Ivan Robert McConnell

    IPC: G01N33/68 ,  G16H50/30 ,  G16H10/40 ,  G16H70/60 ,  G16H20/60

    Abstract: There is provided a method of classifying a biological status of an individual. The method comprising: obtaining a biological sample from a patient; obtaining health-related information from the patient, said information including patient gender; analysing the sample to identify a quantity of each of 2 or more endogenous analytes in the sample; comparing the analyte quantities to reference data from healthy individuals to classify the patient as healthy, pre-diseased, at risk of disease or diseased for at least one health-related condition. The reference data includes data derived from a group of biological samples of individuals having the same gender as the patient and not having a need for medical treatment for a disease or illness, each biological sample of the group of biological samples having been analysed by the same process as used to analyse the patient sample, the process being monitored to maintain a predetermined level of consistency.

    METHOD OF EXTRACTING MATERIAL FROM A FLUID AND EXTRACTOR
    2.
    发明申请
    METHOD OF EXTRACTING MATERIAL FROM A FLUID AND EXTRACTOR 审中-公开

    公开(公告)号：US20200038877A1

    公开(公告)日：2020-02-06

    申请号：US16341436

    申请日：2017-10-13

    Applicant: Randox Laboratories Ltd.

    Inventor： Stuart Jackson ,  Stephen Peter Fitzgerald ,  Ivan McConnell ,  John Lamont

    IPC: B03C1/01 ,  B03C1/28 ,  B01F13/08 ,  C12N15/10

    Abstract: There is provided a method of extracting material from a fluid method of extracting material from a fluid, the fluid being held within a fluid chamber. The method comprises drawing, with a magnetic field generating system, at least one magnetically susceptible member through the fluid around a closed path between at least three points in the chamber, said at least one member being adapted to bind to material in fluid in the chamber. The at least three points are arranged relative to each other in a shape having at least two dimensions, the magnetic field generating system being configured to move the at least on magnetically susceptible member directly between the at least three points, material in the fluid binding to the at least one magnetically susceptible member when it comes into contact with the at least one member as it moves through the fluid.

    KIDNEY DISEASE BIOMARKER
    3.
    发明申请
    KIDNEY DISEASE BIOMARKER 审中-公开
    KIDNEY疾病生物标志

    公开(公告)号：US20150219670A1

    公开(公告)日：2015-08-06

    申请号：US14421382

    申请日：2013-08-12

    Applicant: Randox Laboratories Ltd.

    Inventor： Ivan McConnell ,  Stephen Peter Fitzgerald ,  John Lamont ,  Claran Richardson

    IPC: G01N33/68 ,  G01N33/70 ,  G01N33/573

    CPC classification number: G01N33/6893 ,  C07K14/475 ,  C07K14/8139 ,  C12N9/104 ,  G01N33/573 ,  G01N33/6845 ,  G01N33/70 ,  G01N33/92 ,  G01N2333/47 ,  G01N2333/8139 ,  G01N2333/9108 ,  G01N2333/91188 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/56

    Abstract: The present invention provides a method of stratifying a patient suffering from CKD into one of stages 1-3 of CKD, comprising determining the level of the biomarkers FABP1, γ-GT, AST, creatinine and cystatin C in a sample obtained from the patient and comparing the level of FABP1 in the sample to a control value and the levels of γ-GT, AST, creatinine and cystatin C in the sample to a range of control values for each biomarker, wherein an increased level of FABP1 compared to the control value and levels of γ-GT, AST, creatinine and cystatin C within the range of control values for each biomarker indicate that the patient suffers from stage 1 CKD or wherein an increased level of FABP1 compared to the control value, levels of γ-GT and AST within the range of control values for each biomarker, and increased levels of creatinine and cystatin C compared to an upper threshold of the control range for these biomarkers indicate that the patient suffers from stage 2 or stage 3 CKD.

    Abstract translation: 本发明提供了将患有CKD的患者分为CKD的1-3期的方法，包括测定从患者获得的样品中生物标志物FABP1，γ-GT，AST，肌酐和半胱氨酸蛋白酶抑制剂C的水平，以及 将样品中FABP1的水平与对照值和样品中的γ-GT，AST，肌酐和半胱氨酸蛋白酶抑制剂C的水平进行比较，对每种生物标志物的对照值范围进行比较，其中FABP1水平与对照值相比增加 并且每个生物标志物的对照值范围内的γ-GT，AST，肌酐和半胱氨酸蛋白酶抑制剂C的水平表明患者患有1期CKD或其中FABP1水平与对照值相比增加，γ-GT水平和 在每个生物标志物的对照值范围内的AST和与这些生物标志物的对照范围的上限阈值相比，肌酐和半胱氨酸蛋白酶抑制剂C的水平升高表明患者患有2期或3期CKD。

    DETECTION OF BLADDER CANCER IN MALES
    4.
    发明申请
    DETECTION OF BLADDER CANCER IN MALES 有权

    公开(公告)号：US20240402176A1

    公开(公告)日：2024-12-05

    申请号：US18696817

    申请日：2022-09-29

    Applicant: RANDOX LABORATORIES LTD.

    Inventor： Stephen Peter Fitzgerald ,  Mark Ruddock ,  John Lamont

    IPC: G01N33/574 ,  G01N33/543

    Abstract: Haematuria is a considerable burden within primary and secondary care; too many haematuria patients are referred to secondary care for invasive and expensive investigations that could be managed in primary care. The current invention has identified biomarker combinations with utility for the diagnosis of bladder cancer in males. Using gender specific biomarker algorithms in combination with clinical risks that are associated with bladder cancer, would allow clinicians to better manage haematuria patients in primary care setting.

    Method of extracting material from a fluid and extractor
    8.
    发明授权
    Method of extracting material from a fluid and extractor 有权

    公开(公告)号：US11602757B2

    公开(公告)日：2023-03-14

    申请号：US16341436

    申请日：2017-10-13

    Applicant: Randox Laboratories Ltd.

    Inventor： Stuart Jackson ,  Stephen Peter Fitzgerald ,  Ivan McConnell ,  John Lamont

    IPC: B01F33/452 ,  C12N15/10 ,  B03C1/01 ,  B03C1/28 ,  B01F101/23

    Abstract: There is provided a method of extracting material from a fluid method of extracting material from a fluid, the fluid being held within a fluid chamber. The method comprises drawing, with a magnetic field generating system, at least one magnetically susceptible member through the fluid around a closed path between at least three points in the chamber, said at least one member being adapted to bind to material in fluid in the chamber. The at least three points are arranged relative to each other in a shape having at least two dimensions, the magnetic field generating system being configured to move the at least on magnetically susceptible member directly between the at least three points, material in the fluid binding to the at least one magnetically susceptible member when it comes into contact with the at least one member as it moves through the fluid.

    Kidney disease biomarker
    9.
    发明授权
    Kidney disease biomarker 有权

    公开(公告)号：US10444248B2

    公开(公告)日：2019-10-15

    申请号：US14421382

    申请日：2013-08-12

    Applicant: Randox Laboratories Ltd.

    Inventor： Ivan McConnell ,  Stephen Peter Fitzgerald ,  John Lamont ,  Claran Richardson

    IPC: G01N33/48 ,  G01N33/68 ,  C12N9/10 ,  G01N33/70 ,  G01N33/92 ,  C07K14/81 ,  C07K14/475 ,  G01N33/573

    Abstract: The present invention provides a method of stratifying a patient suffering from CKD into one of stages 1-3 of CKD, comprising determining the level of the biomarkers FABP1, γ-GT, AST, creatinine and cystatin C in a sample obtained from the patient and comparing the level of FABP1 in the sample to a control value and the levels of γ-GT, AST, creatinine and cystatin C in the sample to a range of control values for each biomarker, wherein an increased level of FABP1 compared to the control value and levels of γ-GT, AST, creatinine and cystatin C within the range of control values for each biomarker indicate that the patient suffers from stage 1 CKD or wherein an increased level of FABP1 compared to the control value, levels of γ-GT and AST within the range of control values for each biomarker, and increased levels of creatinine and cystatin C compared to an upper threshold of the control range for these biomarkers indicate that the patient suffers from stage 2 or stage 3 CKD.

Patent Agency Ranking